|
ADPT | Adaptive Biotechnologies Corp |
|
|
ADPT | Adaptive Biotechnologies Corp |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.10 |
| Leverage | 58.37% |
| Market Cap | $ 2.1B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -79.7m |
| Margin | -31.66% |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.